{"id":"W2295530774","doi":"10.3324/haematol.2015.135418","title":"Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto East General Hospital; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Leukemia and Lymphoma Society of Canada; University of Toronto; Leukemia and Lymphoma Society","keywords":"Ruxolitinib; Idelalisib; Janus kinase; Myelofibrosis; Venetoclax; Medicine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; STAT protein; Internal medicine; Janus kinase 1; Clinical trial; stat; Clinical endpoint; Cancer research; Tolerability; STAT3; Leukemia; Signal transduction; Chemistry; Adverse effect; Receptor; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001532521,0.0005068016,0.001094852,0.0001604959,0.000281627,0.0006742934,0.0003707888,0.0009792411,0.002409048],"category_scores_gemma":[0.001334473,0.00011019,0.0005934199,0.000256322,0.0003269724,0.0004287816,0.0001495545,0.001940583,0.0004955116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009271977,"about_ca_system_score_gemma":0.0006189198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004614455,"about_ca_topic_score_gemma":0.001831286,"domain_scores_codex":[0.9996239,0.0001850807,0.00003371261,0.00004363244,0.00005250789,0.0000610608],"domain_scores_gemma":[0.9992704,0.0002772509,0.0001298129,0.00003648288,0.0000603584,0.0002256848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2596256,0.006568798,0.0128622,0.003045409,0.001381108,0.001134797,0.0002789341,0.001467026,0.01786371,0.001227787,0.03820927,0.6563355],"study_design_scores_gemma":[0.6303535,0.2115929,0.05896073,0.001356897,0.001982498,0.003438711,0.0002204655,0.005256829,0.007395064,0.002163835,0.0771937,0.0000849032],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8978514,0.06599122,0.0009774291,0.01383577,0.001179094,0.001430055,0.00205779,0.0001849101,0.01649238],"genre_scores_gemma":[0.9729084,0.0129372,0.0008433007,0.006377304,0.0008787294,0.0006164017,0.001940592,0.0000202227,0.003477786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002409048,"threshold_uncertainty_score":0.008104861,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04686190938523953,"score_gpt":0.3334470027006804,"score_spread":0.2865850933154409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}